Scientific Program (Oral Abstracts) | Poster Abstracts | Speaker List
SECOND INTERNATIONAL SYMPOSIUM
ON THE ROLE OF SOY
IN PREVENTING AND TREATING CHRONIC DISEASESeptember 15-18, 1996
Brussells, Belgium
SCIENTIFIC PROGRAM
(Oral Abstracts)Soy and Cancer
Soybean Anticarcinogens / Anticancer MechanismsThe Bowman-Birk Inhibitor from Soybeans as an Anticarcinogenic Agent
Ann R. Kennedy.
University of Pennsylvania School of Medicine, Philadelphia, PA.Previous research investigations have indicated that certain protease inhibitors are extremely effective at preventing/suppressing carcinogen-induced transformation in vitro and carcinogenesis in animal model systems, as has been reviewed. One protease inhibitor, the soybean-derived Bowman-Birk inhibitor (BBI) has been particularly effective in the ability to suppress the carcinogenic process. BBI has been extensively studied, both as purified BBI (PBBI) and as an extract of soybeans enriched in BBI, called BBI Concentrate (BBIC). PBBI and BBIC have comparable suppressive effects on the carcinogenic process in a variety of in vivo and in vitro systems. BBI appears to be a universal cancer preventive agent. PBBI/BBIC have been shown to suppress carcinogenesis: 1) in three different species (mice, rats and hampsters), 2) in several organ systems/tissue types (colon, liver, lung, esophagus, cheek pouch (oral epithelium) and in cells of hematopoietic origin, 3) in cells of both epithelial and connective tissue origin, 4) when given to animals by several different routes of administration (including the diet), 5) leading to different types of cancer (e.g., squamous cell carcinomas, adenocarcinomas, angiosarcomas, etc.), and 6) induced by a wide variety of chemical and physical carcinogens. BBI, as BBIC, has recently risen to the human trial stage. BBIC achieved Investigational New Drug (IND #34671; sponsor - Ann Kennedy) status from the F.D.A. as of April 1992, and studies to evaluate BBIC as a human cancer chemopreventive agent began. Both BBI and BBIC prevent/suppress malignant transformation in vitro and carcinogenesis in vivo without toxicity, as reviewed in ref. 1. Levels of expression of certain proto-oncogenes and/or proteolytic activities are being utilized as intermediate marker endpoints in human trials of BBIC as a cancer chemopreventive agent.
Soy Symposium Home http://soyfoods.com/symposium/
U.S. Soyfoods Directory Home http:soyfoods.com/
© Copyright 1997
Indiana Soybean Board